Pharming Technologies Completes Acquisition of Abliva
Deal News | Feb 07, 2025 | Globenewswire
Pharming Technologies B.V., a subsidiary of Pharming Group N.V., has completed its recommended cash offer to acquire shares in Abliva AB, with shareholders tendering approximately 87.7% of Abliva's shares. The cash offer was SEK 0.45 per Abliva share, with the acceptance period extended until February 20, 2025. While the offer required more than 90% of shares for full control, Pharming waived this condition to finalize the acquisition. Pharming aims to initiate a compulsory acquisition for the remaining shares and delist Abliva from Nasdaq Stockholm. The offer excludes employee warrants, which Pharming has agreed to acquire separately. The process aligns with regulatory demands, maintaining transparency across varied international financial environments.
Sectors
- Biopharmaceutical
- Pharmaceuticals
- Mergers and Acquisitions
Geography
- Netherlands – Pharming Technologies B.V. is headquartered in the Netherlands, situating the company geographically within Europe.
- Sweden – Abliva AB, the target company, is based in Sweden, where the acquisition activity is primarily occurring.
Industry
- Biopharmaceutical – Pharming Group N.V. is engaged in the biopharmaceutical industry, focusing on treatments for rare diseases, as highlighted by their acquisition of Abliva AB.
- Pharmaceuticals – The acquisition concerns two companies involved in pharmaceuticals and biopharmaceuticals, particularly treating rare diseases, marking a significant industry transaction.
- Mergers and Acquisitions – The article discusses Pharming Technologies' cash offer to acquire a majority stake in Abliva, a notable M&A activity in the sector.
Financials
- SEK 0.45 – Cash offer price per Abliva share tendered by Pharming Technologies.
- 87.7% – Percentage of Abliva shares acquired by Pharming through the offer.
- 68,131,850 – Number of Abliva warrants Pharming agreed to acquire, outside the main offer.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Pharming Technologies B.V. | Acquirer | Company | A wholly-owned subsidiary of Pharming Group N.V., executing the cash offer for Abliva's shares. |
| Abliva AB (publ) | Target Company | Company | A Sweden-based company that is the target of Pharming Technologies' acquisition. |
| Pharming Group N.V. | Parent Company | Company | A global biopharmaceutical company headquartered in the Netherlands, parent company of Pharming Technologies B.V. |
| FTI Consulting | Corporate Finance Advisor | Company | Advising Pharming Group in the transaction, based in the UK. |
| LifeSpring Life Sciences Communication | Public Relations | Company | Handles public relations for Pharming Group, located in Amsterdam. |